

Index

- α -SMA *see* α -smooth muscle actin
- α -smooth muscle actin (α -SMA) 3, 8, 21, 22, 25, 33, 101, 103, 128, 194, 253, 328
- adipocytes 4, 22, 171, 173, 183, 185–187, 194, 204, 328, 330
- adipogenesis 183–187
- angiogenesis 4, 19, 61–63, 70–73, 96, 101–104, 186–190, 202, 245, 247, 248, 257, 258, 260–263, 294, 295, 301, 330–334
- angiotensin receptor blocker (ARB) 37, 140
- animal model 24, 31, 188, 189, 194, 198, 200, 202, 203, 327, 331, 333–335, 360
- antagomiR 11, 290, 301
- antibody 71, 78, 198, 199, 202, 203, 253, 260, 262, 263, 318, 328, 331, 334
- anti-integrins 198
- anti-PD-1 203
- anti-TGF- β 203
- integrin antagonizing 262
- monoclonal 113, 138, 143, 258, 262, 263, 333, 334
- antigen-presenting cell (APC) 59, 62, 170
- antisense oligonucleotides 32, 177, 198, 266
- antitumor function 60–63, 66, 76, 266
- APC *see* antigen-presenting cell
- apoptosis 59, 60, 76, 78, 234, 241, 246, 247, 249, 257, 260, 261, 263, 265, 267
- cancer cell 61, 138
- cellular 290
- chemotherapy-induced 28
- intrinsic 247
- trabectedin-induced 76
- approach 56, 76–79, 127, 137, 140, 141, 201, 203, 205, 266, 315, 316, 360–364, 380, 382–387, 390, 394–396
- albumin 144
- bioprinting 391
- cell-based 388
- decorin-based 142
- engineering-based 396
- fluid 133
- micropillar 386
- pharmacologic 197
- pharmacological 202
- scaffold-based 360, 372, 377, 388
- therapeutic 126, 136, 137, 139, 141, 143, 145, 199, 205
- ARB *see* angiotensin receptor blocker
- architecture 98, 103, 104, 127, 364, 368, 369, 371, 372, 376, 377, 380, 388, 394, 395, 397
- cellular 377, 388, 390, 395, 396
- intestinal 368
- natural 372, 395
- realistic 379
- tissue-relevant 368
- atezolizumab 75, 203, 325
- ATN-161 264, 265
- barrier 12, 34, 73, 124, 147
- body's 67
- immunosuppressive 124, 359
- interstitial stromal 332

- mechanical 396
- physical 10, 124, 331
- tumor-restraining fibrotic 31
- tumor stroma associated 148
- basement membrane 27, 29, 93, 102, 105, 108, 132, 182, 332, 374
- bevacizumab 37, 113, 143, 144, 202, 260, 267, 318
- binding 6, 110, 135, 174, 175, 177, 178, 180, 185, 239, 240, 244, 246, 256
- ATP 199
- disulfide 237
- integrin antibody abituzumab 262
- ligand 173, 234, 236, 237
- ligand-receptor 174, 198
- molecule 263
- transmembrane surface receptors 35
- bioink 380, 381
- biomarker 8, 9, 57, 94–96, 98–114, 288, 295–298, 303
- CAF 38, 95
- cancer cell derived 113
- conventional cancer 114
- immune cell 95, 113
- potential tissue 107
- stromal 94, 95, 104, 109
- tumor 114
- biomaterial 373, 374, 376, 377, 388, 395
- naturally derived 372, 373, 376, 395
- pre-structured 376
- scaffold 388
- synthetic 373, 376, 395
- tissue-derived 376
- bioprinting 364, 377, 379–381, 387–390, 395, 396
- electrospinning-based 377
- extrusion-based 377
- inkjet-based 377
- laser-assisted 377
- stereolithography-based 377
- blood vessel 4, 9, 70, 112, 132, 134, 135, 147, 187–189, 256, 257, 262, 266
- BM *see* bone marrow
- BMP *see* bone morphogenetic protein
- body fluid 295–298, 303
- bone marrow (BM) 21, 22, 65, 77, 108, 187, 328, 330
- bone morphogenetic protein (BMP) 169, 173
- breast cancer model 135, 204, 261, 263, 300
- bioprinted 378
- human 365
- CAF *see* cancer-associated fibroblast
- CAF activation 20, 24, 26, 32, 33, 36, 183
- CAF heterogeneity 24, 38, 101
- CAF inhibition 137, 138, 145, 148
- CAF modulation 20, 32, 38
- cancer 2, 3, 18–20, 26, 27, 55–58, 69–72, 93–95, 98–100, 106–108, 123, 124, 167–174, 176–178, 182–184, 186–188, 190, 192–204, 247–251, 255, 256, 258, 265–267, 302, 303
- brain 18, 374
- breast 18, 19, 22, 24, 26–28, 31, 33, 66, 99, 102, 103, 107, 135, 136, 253, 254, 256, 294, 318, 320, 392
- castration-resistant prostate 262
- colon 19, 113, 256, 258, 300
- colorectal 18, 27, 34, 37, 95, 98, 202, 203, 260, 262, 290, 291, 375
- esophageal 36, 292
- fibrotic 266

- gallbladder 189
- gastric 18, 36, 124, 135, 291
- invasive 56, 94
- lung 24, 56, 57, 59–63, 66, 70, 71, 73, 75, 80, 135, 138, 250, 255, 370
- medullary thyroid 329
- neck 320
- pancreatic 7, 9, 18, 19, 25, 33–35, 37, 108, 110, 124, 126, 135, 261, 263
- rectum 9
- renal 203, 263
- solid 9, 316
- stomach 9
- urothelial 36
- cancer-associated fibroblast (CAF) 3, 10–12, 17–38, 96–103, 124, 127–129, 137–139, 147, 168, 183, 184, 193–197, 202–206, 247–254, 288–292, 327–330, 361, 365–367, 376, 383, 390–392
- cancer biology 96, 106, 112, 113
- cancer cell 2, 22, 23, 27, 28, 55–57, 63, 64, 69–73, 97–99, 111–113, 129, 171, 183, 189–192, 194–198, 200–205, 264–266, 361, 362, 374–377, 379, 383–385, 387, 388
- androgen-dependent prostate 99
- co-cultured patient-derived 369
- culture 375
- early stage 179
- human breast 99
- human colon 99
- invasive 180
- liver 203
- lung 191, 390
- malignant 12, 168, 316
- melanoma 186
- mesenchymal 185
- metastatic 198
- pancreatic 367
- patient-derived 369, 376
- cancer development 23, 26, 80, 113, 168, 331
- cancer diagnosis 55, 94, 108, 113, 288, 296, 297
- cancer growth 36, 95, 108, 171, 172, 188, 201, 205, 261, 264
- cancer initiation 56, 181, 234, 288
- cancer metastasis 27, 187, 256
- cancer-on-chip platform (COC platform) 379, 382–387, 389, 396
- cancer organoids 369, 370, 394, 395
- cancer progression 97–100, 103, 106, 109, 112, 167, 168, 171, 173, 179, 182–184, 191, 193, 195–198, 204–206
- cancer stem cell (CSC) 251, 252, 392
- cancer therapy 28, 36, 57, 58, 73, 75, 77–79, 81, 94, 100, 147, 173
- cancer treatment 20, 173, 198, 202, 264, 297–299, 301, 303, 359, 367
- carbonic anhydrase IX 321
- carcinogenesis 112, 168–170, 173, 175, 177, 179–181, 183, 191, 193, 197, 200
- cathepsins 62, 69, 73, 326
- CD8⁺ T-cell (CTC) 25, 109, 172, 389–391, 396
- cell adhesion 11, 104, 110, 237, 241, 242, 260, 333, 382
- cell attachment 101, 332, 364, 368, 372
- cell-based model 360, 371, 394–396
- cell death 57, 96, 169, 170, 196, 202, 256

- cell migration 127, 129, 188, 198, 237, 241, 245, 250, 261, 330, 332
 - CAF-induced gastric cancer 291
 - collective 129
 - endothelial 301
 - epithelial 194
- cell proliferation 6, 35, 59, 60, 62, 74, 104, 169, 170, 180, 192, 241, 250
 - cancer 77
 - endothelial 62
 - epithelial 62, 258
 - factor-induced 241
 - neoplastic 9
- cellular interaction 126, 332, 360, 361, 370, 371, 375, 379, 382, 384, 385, 390, 391, 394–396
- cellular process 11, 129, 287, 391, 397
- cetuximab 199, 260, 262
- chemokines 26, 27, 29, 67, 68, 72, 139, 234, 288, 289, 326
 - antiangiogenic 70
 - inflammatory 191
- chemoresistance 7, 23, 28, 30, 33, 36, 106, 125, 126, 290, 331
- chemotherapy 2, 5, 7, 10, 35, 38, 70, 73, 76, 78, 198, 199, 263–265, 393
- chimeric antigen receptor 64, 266
- cilengitide 199, 263, 318
- clinical trial 10, 12, 32, 33, 35, 36, 59, 61, 176, 177, 197–200, 202, 203, 205, 260–262, 264, 267, 302, 325, 326
- COC platform *see* cancer-on-chip platform
- collagen 6, 18, 97, 98, 104–107, 127–129, 140, 141, 236, 237, 249, 250, 328, 330–332, 371, 372, 374, 385, 387, 389
 - fibrillar 104, 142
 - type III 95, 110
- collagenase 140–142
- collagen receptor 35, 237, 239
- colony-stimulating factor (CSF) 5, 67, 109, 193
- combination therapy 59, 61, 62, 75, 79, 128, 262
- computational model 361, 391, 393, 394
- computed tomography (CT) 9, 316, 321, 324
- connective tissue 1, 18, 21, 194, 248
- connective tissue growth factor (CTGF) 10, 35, 100, 196
- crosslinking 104, 127, 147, 373, 374
- crosstalk 56, 58, 100, 173, 183, 185, 192, 195, 196, 200, 201, 203, 252, 253, 360–362, 365
 - bidirectional 19, 36
 - cellular 111
 - paracrine 28, 361, 362
 - reciprocal 183
 - stroma-cancer 20
 - TGF- β -mediated 198
- CSC *see* cancer stem cell
- CSF *see* colony-stimulating factor
- CT *see* computed tomography
- CTC *see* CD8⁺ T-cell
- CTGF *see* connective tissue growth factor
- CTL *see* cytotoxic T lymphocyte
- cutaneous T-cell lymphoma 302
- cyclin-dependent kinase 179
- cysteine 36, 106, 173
- cytokines 1, 3, 5, 30, 32, 67–69, 72, 109, 183, 184, 189, 195–197, 234, 253, 254, 288, 289, 292, 293
 - anti-tumour 201
 - cancer cells-secreted 26
 - immunosuppressive 191, 193
 - mitogenic 10
 - multifunctional 138

- pro-inflammatory 249
- tumor cell-derived 289
- tumor-derived 22
- tumor-promoting 34
- tumor-suppressing 32
- cytotoxicity 192, 260, 265, 266
- cytotoxic T lymphocyte (CTL) 63, 191, 205, 206
- DC *see* dendritic cell
- decellularized ECM (dECM) 375, 376, 380, 389, 395, 396
- dECM *see* decellularized ECM
- degradation 10, 102, 108, 142, 146, 177, 179, 189, 287, 296, 299
- dendritic cell (DC) 3, 59, 75, 300, 324, 326
- desmoplasia 1, 18, 20, 31, 110, 139, 183, 248, 253
- desmoplastic reaction 18, 32, 103, 126, 127, 137, 147, 194, 249, 253
- diagnosis 57, 94, 112, 113, 124, 295, 296, 303, 331, 336
- disease 102, 103, 123, 169, 301, 328, 332
 - cardiovascular 184
 - chronic kidney 332
 - chronic obstructive pulmonary 381
 - fibrotic lung 24
 - inflammatory 327
 - non-malignant 34
 - oncologic 332
- DOX *see* doxorubicin
- doxorubicin (DOX) 28, 138, 141, 144, 204, 264, 265, 365
- drug 136, 143, 204, 205, 255, 259–261, 267, 380–382, 385, 393, 394, 396
 - anti-angiogenic 387
 - anticancer 137
 - anti-diabetic 36
 - anti-fibrotic 34, 140
 - anti-hypertensive 140
 - chemotherapy 365
 - immunotherapeutic 380
 - nanoparticle-based 140
 - tumor-suppressing 263
- drug delivery 12, 103, 143, 144, 234, 255, 265, 322, 331, 335, 392
- drug efficacy 123, 380, 383, 394, 396
- drug penetration 34, 110, 143, 385, 394
- drug resistance 10, 12, 36, 124, 126, 133, 135, 136, 247, 266
- dynamic contrast enhanced MRI 321
- EC *see* endothelial cell
- E-cadherin 18, 180, 246, 262, 332, 366
- ECM *see* extracellular matrix
- ECM component 3, 73, 106, 129, 142, 145, 190, 237, 250, 366, 374, 375
- ECM composition 106, 189, 375, 376, 397
- ECM degradation 31, 69, 73, 96, 136, 140, 142, 148
- ECM protein 3, 6–8, 104, 107, 127, 129, 235, 236, 246, 250, 253, 255, 257, 374, 375
- ECM remodeling 29, 107, 110, 193–195, 234, 247, 249
- ECM stiffness 31, 127, 128, 251, 335
- effectors 175, 179, 182, 183, 185
- EGF *see* epidermal growth factor
- EGFR *see* epidermal growth factor receptor
- electron paramagnetic resonance (EPR) 320, 321, 388
- EMT *see* epithelial–mesenchymal transition

- endothelial cell (EC) 3, 4, 21, 22, 72, 100–102, 187–189, 245, 257, 258, 260, 262, 265, 266, 294, 295, 301, 327, 328, 330, 331, 375, 376, 380, 381, 386–388
- endothelial progenitor cell (EPC) 102, 294
- enzyme 6, 10, 104, 105, 142, 179, 181, 194, 241, 330, 335
- EPC *see* endothelial progenitor cell
- epidermal growth factor (EGF) 10, 57, 69, 71, 170, 242, 258, 326, 334, 392
- epidermal growth factor receptor (EGFR) 57, 170, 242, 244, 255, 256, 333
- epithelial cell 21, 22, 26, 65, 97, 182, 195, 238, 241, 246, 252, 253, 258
 - alveolar 381, 386
 - diseased 262
 - human-derived prostatic 26
- epithelial–mesenchymal transition (EMT) 19, 21, 28, 63, 73, 101, 105, 106, 168, 182, 185, 186, 193, 194, 198, 199, 246, 247, 326, 392
- EPR *see* electron paramagnetic resonance
- ERK *see* extracellular-signal-regulated kinase
- EV *see* extracellular vesicle
- exosomes 26, 192, 193, 265, 295, 297, 301
- extracellular domain B 333
- extracellular matrix (ECM) 5, 6, 11, 17, 18, 29, 97, 98, 104–107, 123, 124, 127–129, 139, 140, 142, 146–148, 234, 235, 237, 241, 248–250, 330–333, 335, 365–368, 374–376, 380, 381
- extracellular-signal-regulated kinase (ERK) 74, 185, 257
- extracellular vesicle (EV) 2, 113, 391
- fabrication 364, 365, 368, 375–377, 380, 382, 384–388, 391, 395
- FAK *see* focal adhesion kinase
- FAK phosphorylation 261, 264
- FAK signaling pathway 257, 267
- FAP *see* fibroblast activation protein
- fatty acid oxidation 60
- FGF *see* fibroblast growth factor
- FGFR *see* fibroblast growth factor receptor
- fibroblast 1–3, 17, 18, 24, 25, 99–101, 194, 201, 238, 248, 250, 253, 254, 291, 327, 328, 330, 331, 379, 380, 384, 385
 - activated 1, 2, 21, 33, 100, 101, 103, 289, 328
 - dermal 262
 - embryonic 252, 253, 299
 - interlobular 22
 - intralobular 22
 - mammary gland 253
 - mesenchyme-derived 24
 - non-adventitial 24
 - quiescent 26, 289, 290
 - radiolabeled 328
 - stromal 138, 195, 252, 253, 390
- fibroblast activation protein (FAP) 3, 10, 21, 25, 101, 103, 138, 145, 194, 202, 328, 329
- fibroblast growth factor (FGF) 27, 102, 138, 187, 247, 250, 257, 258, 326
- fibroblast growth factor receptor (FGFR) 10, 138, 145, 247
- fibronectin 6, 97, 98, 104, 107, 236, 237, 239, 250, 255, 256, 330, 332, 333, 373, 374
 - cell surfaces depositing 250

- receptors binding 237
- fibrosis 128, 194, 248, 328
 - organ 20
 - pathological 106
 - pulmonary 35, 140, 332
- fibrotic desmoplastic tissue 100
- fluorescence-activated cell sorting 194
- fluorescence molecular tomography 321
- fluorescence resonance energy transfer 127
- focal adhesion kinase (FAK) 10, 11, 104, 239–242, 247, 254, 256, 266
- GAG *see* glycosaminoglycan
- gemcitabine 28, 32, 34, 35, 61, 128, 139, 261, 263, 290, 393
- gene 19, 56, 59, 67, 70, 79, 98, 101, 178, 179, 181, 182, 253, 294, 295, 299
 - adipose 184
 - anti-apoptotic 181
 - mutated 57
 - pro-apoptotic 181
 - protumoral 292
 - reporter 322, 323, 325, 337
 - tumor promoter 291
 - tumor-promoting 72
 - tumor-suppressing 19
- gene expression 135, 141, 181, 250, 287
- genetic alteration 56, 136, 369
- glioblastoma 65, 98, 141, 144, 146, 199, 200, 248, 254, 255, 258, 261, 263, 264
- glioblastoma cell 256, 257, 366, 376, 380
- glioblastoma-on-chip model 376
- glioma 33, 169, 182, 200, 247, 324, 327, 335
- glycoprotein 6, 106, 174, 235, 328
- glycosaminoglycan (GAG) 6, 105, 134
- Golgi apparatus 18, 105, 174
- growth factor 1, 2, 5, 10, 11, 18, 20, 26–30, 68, 69, 71, 100, 102, 124, 127, 132, 133, 241, 242, 244
 - active 6
 - angiogenic 245
 - connective tissue 10, 35, 100
 - endothelial 392
 - epidermal 10, 69, 242
 - epithelial 242
 - fibroblast 27, 102, 187, 247
 - hepatocyte 10, 26, 99, 201, 242, 301
 - milk fat globuleepidermal 71
 - platelet-derived 100, 132, 137, 247
 - pleiotropic 100
 - pro-angiogenic 189, 193
- growth factor receptor 11, 242–245, 258
 - endothelial 242
 - epidermal 57, 170
 - epithelial 244
 - hepatocyte 242
- HCC *see* hepatocellular carcinoma
- heat shock factor (HSF) 10, 19
- Hedgehog inhibitor 37, 38
- Hedgehog pathway 333
- Hedgehog signaling 32, 252
- hematopoietic stem cell (HSC) 21, 101
- hepatocellular carcinoma (HCC) 73, 74, 100, 101, 202, 293, 296, 302
- hepatocyte growth factor (HGF) 10, 26, 99, 100, 201, 242, 244, 301
- herpes simplex virus (HSV) 134, 142, 325
- heterospheroid 364–368, 384

- HGF *see* hepatocyte growth factor
 HIF *see* hypoxia-inducible factor
 HIF-1 5, 134, 136, 144, 146
 HIF-1 α 30, 60, 135, 136, 294
 homeostasis 6, 34, 132, 170, 330
 Hooke's law 130, 131
 HPOC *see* hybrid protein oxygen carrier
 HSC *see* hematopoietic stem cell
 HSF *see* heat shock factor
 HSV *see* herpes simplex virus
 hyaluronan 18, 95, 110, 129, 333, 335
 contrast labeled 333
 endogenous 333
 exogenous 333
 hyaluronic acid 6, 10, 140, 333, 372–374, 393
 hyaluronidase 140–142, 335
 hyase 140, 141
 hybrid protein oxygen carrier (HPOC) 144, 146
 hydrogels 361, 369, 372, 374–376, 383–388, 394
 hydrophobicity 300, 382
 hypoxia 5, 7, 26, 29, 33, 123, 125, 126, 130, 136, 139, 143, 144, 146–148, 321
 chronic 135
 diffusion-limited 135
 exogenous 322
 intermittent 135
 intratumoral 29
 transient 135
 hypoxia-inducible factor (HIF) 60, 134, 294
 hypoxia response element 135
 hypoxic conditions 30, 134–136, 144

 ICB *see* immune checkpoint blocker
 idiopathic pulmonary fibrosis (IPF) 140, 332

 IFP *see* interstitial fluid pressure
 imaging 315, 316, 319–321, 323, 324, 326–328, 332, 333, 337
 bimodal NIR/PA 321
 clinical 334
 immune cell 322
 lymph node 320
 macrophage 327
 magnetic resonance 9, 316, 327, 333
 multispectral optoacoustic 334
 non-invasive 326
 optical 9, 316, 324, 337
 photoacoustic 316, 321
 pretreatment 332
 radioisotope 327
 reporter gene 324, 325
 spectroscopic 336
 immune cell 3, 11, 12, 57, 58, 70, 112, 113, 183, 184, 189, 190, 193, 194, 202–205, 246, 247, 292–294, 316, 322, 323, 390, 392, 393
 adaptive 97, 98, 292
 infiltrated 30
 inflammatory 2
 innate 191, 192
 marrow-derived 254
 non-mesenchymal 288
 immune checkpoint blocker (ICB) 57, 60, 64
 immune checkpoint therapy 57, 61, 75, 79, 370
 immune response 59, 63, 67, 72, 109, 142, 293, 302, 325, 360, 393
 immune system 10, 61, 62, 68, 108, 109, 113, 246, 266, 359, 360, 367, 391, 394
 immunosuppression 12, 30, 31, 33, 168, 184, 196, 202, 205, 206, 247, 248, 251, 254
 immunosurveillance 8, 67, 100, 183, 190–192, 202, 392

- immunotherapy 2, 11, 109, 143, 144, 249, 297, 322, 324, 325, 367, 392
- inflammatory cell 1, 109, 189, 190
- inhibitory apoptosis protein 241
- integrin 6, 11, 35, 174, 177, 183, 194, 198, 233–250, 252–260, 262–267, 318, 332, 333
 - α -I domain 237
 - allosteric 239
 - collagen-binding 253
 - fibronectin binding 246
 - heterodimeric 237
 - role of 248, 249, 251, 253, 255, 257, 267
 - tumoral 265
- integrin receptor 6, 11, 235, 239, 241
- interleukin 5, 23, 109, 179, 195, 317, 325
- interstitial fluid pressure (IFP) 6, 110, 112, 123, 126, 129, 132–134, 136, 139–141, 143, 147
- IPF *see* idiopathic pulmonary fibrosis
- kinase 74, 178, 179, 188, 240
 - anaplastic lymphoma 57
 - cyclin-dependent 179
 - extracellular-signal-regulated 74
 - glycogen synthase 179
 - integrin-linked 241
 - threonine-protein 256
 - thymidine 325
- kinase inhibitor 10, 137, 143, 179, 180, 198, 199
- Kupffer cell 67
- laminins 6, 18, 29, 101, 104, 105, 196, 237, 250, 330, 332, 372–374
- Langerhans cell (LC) 65, 67
- LAP *see* latency-associated peptide
- large latent complex (LLC) 174, 176
- latency-associated peptide (LAP) 174, 202
- latent TGF- β binding protein (LTBP) 174, 176, 177, 198
- LC *see* Langerhans cell
- leukemia inhibitory factor (LIF) 20, 33
- leukocytes 61, 236, 238, 251, 254
- LIF *see* leukemia inhibitory factor
- ligand 26, 57, 61, 175, 202, 236, 238, 239, 256
 - α v β 3 integrin 264
 - factor-related apoptosis-inducing 76
 - immobilized 240
 - immune checkpoint 72, 74, 75
 - motif chemokine 21
 - physiological 237
 - programmed death 325
- liposomes 71, 81, 264, 265, 299
- LLC *see* large latent complex
- losartan 37, 140, 148
- LTBP *see* latent TGF- β binding protein
- lung tumorigenesis 62, 66
- lymph node metastasis 7, 71, 102, 103, 192, 196, 256
- lymph nodes 133, 320, 321, 324, 326
- lymphocytes 9, 65, 191, 206, 238, 370, 371
- lymphomas 97, 139, 169, 291, 302
- macromolecule 140, 141, 147, 234, 320
- macrophage 5, 64–69, 72–74, 76, 77, 79, 100, 103, 109, 112, 292, 293, 316, 324, 327, 366, 367, 392

- activated 68
- arginase-associated 74
- bone-marrow-derived definitive interstitial 65
- embryonic-derived interstitial resident 66
- embryonic-derived resident 66
- human PBMC-derived 70
- infiltrated 380
- monocyte-derived 292
- murine 76
- peritoneal 191
- pro-inflammatory M1 293
- protumoral M2 293
- red pulp 67
- sac-derived primitive interstitial 65
- spleen 67
- tissue-resident 65, 67, 249
- tumor associated 191, 326
- macrophage infiltration 78, 293
- macrophage polarization 68, 79, 193
- macrophage stimulatory protein 201
- magnetic resonance imaging (MRI) 9, 316, 321, 324, 326–328, 333, 334, 336, 337
- magnetic resonance spectroscopy (MRS) 321, 336, 337
- malignancy 26, 70, 94, 99, 125, 246, 317
- malignant cell 3, 26, 28, 30, 32, 94, 173, 182, 183, 187, 328, 331
- MAPK *see* mitogen-activated protein kinase
- marker 3, 69, 70, 102, 103, 194, 204, 291, 297, 298, 321, 325, 327, 332
 - CAF 22, 33, 138
 - basal 98
 - cell surface 66, 101
 - endothelial 21, 319
 - gene 380
 - inflammatory 33
 - mesenchymal 21, 332
 - myofibroblast 128
 - prognostic 253, 256
 - serum tumor 112
- matrix metalloproteinase (MMP) 5, 6, 18, 21, 72, 73, 102, 108, 134, 140–142, 195, 196, 248, 250, 326, 328, 332, 334, 335
- MDSC *see* myeloid-derived suppressor cell
- melanoma 63, 74, 75, 77, 135, 139, 142, 145, 256, 263, 361, 370
- mesenchymal stem cell (MSC) 21–23, 97, 101, 102, 193, 248, 300, 330
- mesenchymal transition 21, 63, 73, 96, 128, 182, 246, 252, 256, 326
- mesothelioma 191, 199, 383
- metabolism 9, 30, 60, 126, 193, 251, 335, 336
 - arginine 60, 73
 - choline-phospholipid 336
 - energy 96
 - glucose 336
 - glycolytic 36, 196
 - progesterone 19
- metabolites 23, 67, 69, 187, 337
- metastasis 4–7, 9, 10, 26–28, 31, 32, 61–63, 71–73, 76, 77, 80, 95–100, 102, 103, 105, 106, 141, 142, 147, 182, 183, 198–200, 204, 205, 246–248, 255, 256, 261, 262, 264–267
- bone 27, 99, 262
- cancer cell 28, 72, 256
- hepatic 328
- lymphatic 24
- peritoneal 318
- pulmonary 142
- microbubbles 318–320, 365

- microenvironment 2, 3, 95, 97, 112, 147, 148, 189, 191, 234, 252, 255, 256, 288, 363
 - cellular 246
 - heterogenous 321
 - immune 249
 - immunosuppressive 5, 7, 10
 - inflammatory 194
 - pro-tumourigenic 197
 - tumour 167
- microglia 65, 67, 327
- microRNA (miRNA) 5, 11, 22, 287–303
- microwells 365, 383, 384
- miRNA *see* microRNA
- mitochondrial activity 30, 36, 136, 196
- mitochondrial calcium uniporter channel 136
- mitogen-activated protein kinase (MAPK) 29, 179, 185, 242
- MMP *see* matrix metalloproteinase
- molecular pathways 167, 169–171, 173, 181, 204
- monocyte 60, 67, 76, 77, 109, 189, 238, 249, 293, 297, 367
- mouse model 35, 59, 71, 107, 128, 138, 189, 191–193, 201, 264, 265, 267, 327, 337
- MPC *see* metastatic pancreatic cancer
- MRI *see* magnetic resonance imaging
- MRS *see* magnetic resonance spectroscopy
- MSC *see* mesenchymal stem cell
- murine model 26, 31, 66, 135, 199
- mutation 36, 57, 96, 98, 101, 136, 169, 170, 181, 247, 255
 - genetic 252
 - genomic 21
 - harbor 101
 - tumor-suppressing 22
- myCAF *see* myofibroblastic CAF
- myeloid-derived suppressor cell (MDSC) 58, 60, 61, 74, 80, 192, 193, 293, 297
- myofibroblastic CAF (myCAF) 23, 25, 195, 201
- myofibroblast 1, 18, 21, 101, 102, 194, 196, 238, 246, 253
- nanomedicine 140, 265, 383
- nanoparticle 81, 143, 264–266, 300, 301
- natural killer cell (NK cell) 3, 59, 191, 289, 292, 293
- neoangiogenesis 317–320
- neutrophils 3, 60–62, 97, 109, 189, 191, 238
 - circulating 61
 - immunosuppressive 57
 - tumor-associated 58, 61, 191
- NK cell *see* natural killer cell
- non-cancer cell 168, 171, 183, 186, 197, 200, 201, 205
- non-small cell lung carcinoma (NSCLC) 24, 25, 28, 37, 56, 59, 61, 62, 252, 253, 255, 367
- NSCLC *see* non-small cell lung carcinoma
- nutrient 7, 112, 132, 134, 147, 187, 336, 365, 373, 384, 385, 388
- oncogenesis 322, 328, 330, 333–335
- OOO platform *see* organ-on-chip platform
- organoids 360, 363, 368–370, 388, 396
 - cell-based 369
 - patient-derived 366, 369
- organ-on-chip platform (OOO platform) 381–383, 385, 386, 388, 389, 391, 393, 395, 396
- osteopontin 21, 106, 107, 252

- paclitaxel 79, 265
- pancreatic ductal adenocarcinoma (PDAC) 3, 18, 25, 28, 31, 34, 103, 127, 128, 133, 136, 139, 250, 252, 266, 267, 365
- pancreatic stellate cell (PSC) 21, 23, 25, 34, 35, 108, 250, 252, 291, 369
- PDAC *see* pancreatic ductal adenocarcinoma
- PDGF *see* platelet-derived growth factor
- peptide 76, 138, 145, 174, 258, 261, 265, 331, 333, 334
- pericytes 3, 4, 22, 100, 101, 132, 138, 187, 188, 238, 288, 294, 295
- periostin 106, 107, 254
- PET *see* positron emission tomography
- pharmacological inhibitor 177, 189, 199, 205, 206
- phenotype 3, 64, 65, 68–70, 81, 101, 125, 168, 195, 249, 255, 292
 - activated macrophages 68
 - aggressive 23
 - anti-tumorigenic M1 292
 - cancer cell 135
 - cancerous 71
 - cellular 11
 - heterogeneous 70
 - human TAM
 - immunosuppression 74
 - iCAF 33, 34
 - immune 57, 59, 108
 - immunosuppressive 59, 60, 63, 72, 73, 75, 76, 300
 - inflammatory 3
 - invasive 28, 100, 127
 - invasive tumor 294
 - macrophage 68
 - matrix-producing contractile 330
 - metastatic tumor 128
 - myofibroblast 3
 - proinflammatory 68
 - proliferative 66
 - pro-metastatic 204
 - pro-tumourigenic 191, 193, 292
 - secretory 3, 33
 - tumor-associated 375
- phosphorylation 74, 175, 177–179, 181, 188, 196, 199, 242, 256
- platelet-derived growth factor (PDGF) 5, 11, 26, 29, 100, 132, 137, 138, 144, 233, 242, 247, 248
- polarization 5, 11, 35, 68, 186, 193, 367
- positron emission tomography (PET) 9, 316, 318–321, 324, 325, 329, 334, 335, 337
- preclinical model 78, 133, 140, 141, 148, 168, 173, 198, 202, 203, 262, 266
- precursor 22, 34, 66, 185–188
- prognosis 2, 3, 9, 70, 71, 94, 95, 103, 105, 108, 109, 112, 184, 187, 288, 291, 295–297
- prostate cancer 9, 18, 28, 77, 107, 108, 189, 198, 202, 256, 261–264
- protease 62, 141, 147, 189, 326
 - extracellular 250
 - matrix-degrading 248
 - proangiogenic 62
 - serine 73
- protein 2, 6, 97, 101, 107, 108, 110, 175, 178, 179, 182, 202, 203, 239–241, 328, 335
 - angiogenesis associated 319
 - angiogenic 260
 - cell-adhesion 382
 - core 105, 142
 - cytoplasmic 173, 182
 - cytoskeleton 183

- cytosolic 175
- downstream 318
- extracellular 359
- fibroblast-activation 101, 194
- fluorescent 328
- matricellular 106, 107
- matrix-degrading 255, 328
- miR-499-mediated 301
- plasma 237
- sensor 252
- structural 106, 330, 331
- transmembrane 175, 234
- tumour 170
- tyrosine-phosphorylated 240
- protein expression 18, 94, 252, 334
- proteoglycans 6, 29, 97, 98, 105, 106, 134, 141, 330, 333, 334, 373, 374
- PSC *see* pancreatic stellate cell
- radiotherapy 5, 60, 128, 199
- Raman spectroscopy 316
- reactive nitrogen species 62
- reactive oxygen species (ROS) 23, 29, 60, 62, 125, 136, 144, 146, 326
- receptor 70, 72, 76, 77, 143, 145, 174, 175, 177, 178, 188, 233–235, 237, 239, 242, 244, 245, 254, 255, 327
- estrogen 102
- folate 327
- insulin 242
- leukocyte 237, 239
- non-RGD 239
- somatostatin 327
- thrombospondin 239
- receptor-regulated SMAD (R-SMAD) 175, 177–179
- regulatory T-cell (Treg) 24, 30, 59, 63, 75, 80, 109, 192, 203, 247, 251
- remodeling 1, 137, 172, 235, 248, 249, 255, 335
- reprogramming 25, 30, 36, 79–81, 144, 290, 291, 335
- resistance 2, 4, 5, 62, 64, 96, 126, 133–136, 184, 193, 194, 247, 248, 250, 255
- multidrug 136
- therapeutic 147
- tumor cell 10
- RGD 237, 246, 263, 265, 318
- RGD peptide 263–265, 301
- ROS *see* reactive oxygen species
- R-SMAD *see* receptor-regulated SMAD
- scaffold 194, 235, 236, 372–377, 380, 381, 384, 386–389, 395, 396
- alginate 380
- cell-laden 388
- polymeric 376
- polymeric porous 372
- synthetic 366, 388
- scaffold-based model 364, 388, 389
- SCLC *see* small cell lung carcinoma
- SDF *see* stroma-derived factor
- secretion 22, 26, 68, 71, 72, 174, 189, 192, 193, 195, 197, 201, 202, 249, 252, 254
- signal 5, 23, 67, 174, 177, 178, 235, 237, 242, 254, 318, 324
- signaling 128, 168, 170, 173, 177, 195, 205, 233–235, 239–242, 244, 245, 254
- autocrine 247
- autonomous 240
- bidirectional 235, 239, 258
- collaborative 242
- FAK-mediated 105
- growth factor receptor 244
- increasing B-catenin 130
- inside-out 11

- integrin-mediated 253
- intracellular 241
- oncogenic c-Met 100
- outside-in 11
- STAT3 62
- signaling pathway 22, 24,
 - 168–171, 173–175, 177,
 - 179–182, 188–190, 197, 198,
 - 200, 201, 205, 235, 236, 243,
 - 245, 247, 333, 334
- single-photon emission computed tomography (SPECT) 9, 316, 319–321, 325, 326, 337
- SLC *see* small latent complex
- small cell lung carcinoma (SCLC) 24, 56, 255, 367
- small latent complex (SLC) 174, 176
- solid stress 111, 112, 123, 125, 127, 129–131, 136, 147
- sonic hedgehog 32, 71, 128, 252, 266
- SPECT *see* single-photon emission computed tomography
- spheroid 12, 254, 360, 363–365, 367, 368, 371, 378, 379, 383, 384, 388
- breast ductal carcinoma 384
- collagen matrix 250
- encapsulated 367
- entrap 383
- glioma 387
- multi-cellular 364
- patient-derived glioma 367
- stem cell 21, 23, 71, 98, 102, 193, 194, 248, 328, 368, 369
- stress 94, 104, 126, 129–132, 140, 147, 257, 389
- stroma-derived factor (SDF) 10, 19, 22, 27, 102, 251, 253
- stromal cell 5, 7–9, 58, 95–97, 100, 101, 112, 247–250, 252, 253, 267, 288, 328, 330, 366, 378, 392
- system
 - 3D-bioprinted 372, 387
 - 7-channel microfluidic 384
 - dynamic culture 390
 - liposomal 264
 - lymphatic 94, 320, 393
 - microfluidic-based 372
 - micropillar 385
 - miRNA delivery 300
 - nonviral-based 299
 - non-viral vector 299
 - organoid-based 371, 389
 - organ-on-chip 371
 - parasympathetic nervous 389
 - physical support 99
 - physiological 97
 - pumping 390
 - scaffold-based 372
 - skeletal 318
- TAM *see* tumor-associated macrophage
- TAM infiltration 71, 75, 255
- TAM population 65, 66, 69, 76, 77
- TAN *see* tumor-associated neutrophil
- T-cell 5, 30, 31, 109, 206, 266, 289, 292, 324, 325
- T-cell protein tyrosine phosphate 244
- T cell receptor (TCR) 74, 192
- TCR *see* T cell receptor
- TF *see* transcription factor
- TGF *see* transforming growth factor
- TGF- β 11, 26, 27, 29, 30, 32, 71, 100, 101, 168, 170, 173, 174, 176, 177, 179–197, 199–201, 203–206, 246, 247, 250, 252, 326
- TGF- β 1 20–22, 24, 188, 191, 246, 294
- TGF- β inhibitor 37, 191, 197, 198, 200–203

- TGF- β receptor 32, 100, 175, 177, 179, 188, 199, 200
 therapeutic efficacy 10, 124, 125, 134, 147, 303, 316, 331, 336, 393
 therapy 73, 74, 94, 99, 184, 191, 193, 203, 205, 206, 316, 320, 325
 anti-MARCO 79
 anti-PD1 324
 anti-TGF- β 177, 206
 anti-VEGF 201
 bifunctional 203
 cell-targeted 64
 clinical 77
 combinational 203, 265, 266
 conventional 124
 immune 79, 168
 photodynamic 144
 radionuclide 328, 337
 tissue 64, 99, 101, 113, 125–130, 132, 167, 169, 264, 330, 331, 362, 363, 374–376, 381, 383–390, 394, 395
 3D-bioprinted 389
 artificial 396
 biological 372
 bioprinted 396
 breast 22, 102, 107, 111, 253
 confluent 392
 embryonic 64
 engineered 395
 epithelial 1, 97, 201
 fibrotic 393
 healthy 17, 27, 29, 125, 126, 129, 133, 147
 malignant 105
 mesenchymal 102
 non-cancerous 201, 383
 scaffold-based 383
 tumor 1, 4, 9, 28, 31, 125–127, 129, 132, 292, 297, 298, 362, 384, 386
 virtual 391
 tissue homeostasis 97, 138, 246
 tissue morphogenesis 330, 395
 tissue remodeling 68, 258, 332, 334
 tissue stiffness 105, 106, 123, 126–130, 136
 tissue stroma 97, 124, 171, 200
 TKI *see* tyrosine kinase inhibitor
 TME *see* tumor microenvironment
 TME components 57, 59, 337, 365, 367, 369–371, 375–377, 379, 382, 383, 388, 393
 TNBC *see* triple-negative breast cancer
 TNF- α 63, 68, 69, 186, 257, 258, 265, 293
 toxicity 176, 261–264, 266, 326, 333, 381
 tracer 318, 320, 322, 325–328, 332, 333, 335, 336
 angiogenic 319
 anti-PD-1 325
 clinical hypoxia 321
 fluorescence imaging 334
 fluorescent 318, 330
 NIRF 328
 nuclear imaging 333
 PET 321, 325, 327, 332
 radiolabeled 318, 327
 SPECT 318, 320, 329
 transcription factor (TF) 20, 67, 175, 177, 185
 transdifferentiation 21, 98, 99, 185, 192, 299
 transformation 21, 26, 61, 101, 293, 328, 389
 transforming growth factor (TGF) 5, 8, 10, 19, 20, 102, 109, 168, 169, 171, 173–175, 177, 183, 184, 187–191, 195–199, 201, 202, 204, 205
 Treg *see* regulatory T-cell
 triple-negative breast cancer (TNBC) 136, 392
 TSR *see* tumor-stroma ratio

- tumor 2-7, 9, 10, 55, 56, 65,
 - 66, 70, 71, 94-97, 99, 100,
 - 104-106, 108-114, 124-127,
 - 129-134, 147, 148, 245-249,
 - 254-256, 290-294, 316, 317,
 - 319-322, 326-328, 362, 363,
 - 392-394
- afibrotic 245
- bladder 106
- brain 65, 66
- breast 4, 19, 290, 291
- central nervous system 261,
 - 264
- colon 300
- drug-resistant 333
- fibrotic 126, 127, 137, 147, 248,
 - 249, 374
- human 62, 70, 73, 102, 109,
 - 129, 301
- hypoxic 125
- invasive 106
- lung 56, 57, 59, 62, 69, 70, 290
- malignant 104, 112, 167, 171,
 - 205, 253, 327
- metastatic 297
- murine 143
- neuroendocrine 56, 329
- nonfibrotic 248, 249
- ovarian 290
- pancreatic 9, 289-291
- penetration-resistant 133
- prostate 33, 290
- solid 1, 9, 17, 36, 37, 104, 133,
 - 135, 139, 140, 260-262, 264,
 - 267
- tumor aggressiveness 33, 111,
 - 247, 293
- tumor angiogenesis 99, 188-190,
 - 193,
 - 258, 294
- tumor-associated macrophage
 - (TAM) 3, 5, 56, 58, 60, 62-81,
 - 109, 124, 191, 248, 249, 254,
 - 255, 288-290, 292, 293, 326,
 - 327, 367
- tumor-associated neutrophil (TAN)
 - 58, 61, 62, 191
- tumor cell 6, 7, 10-12, 23, 26, 28,
 - 30, 31, 101, 108, 109, 111,
 - 112, 124, 234, 235, 248-250,
 - 252, 253, 255, 288, 289, 291,
 - 292, 365, 366, 378-380, 389,
 - 390, 392
- tumor development 56, 72, 76,
 - 80, 97, 98, 124, 289, 292, 294,
 - 316, 332
- tumor growth 19, 62, 63, 70-72,
 - 74, 75, 77, 79, 80, 97, 99,
 - 129-131, 138, 170, 187, 188,
 - 191, 193, 195, 198-201, 204,
 - 247-249, 251, 252, 261-263,
 - 292-295, 300, 301
- tumorigenesis 2, 6, 9, 26, 27, 56,
 - 62, 63, 66, 72, 80, 81, 100, 105,
 - 168, 179, 181, 183, 184, 189,
 - 192, 198, 200
- tumorigenicity 24, 34, 252, 257,
 - 291
- tumor imaging 112, 322, 330, 332,
 - 334
- tumor initiation 32, 61, 66, 71, 76,
 - 101, 250, 292
- tumor interstitium 112, 132, 320
- tumor invasion 6, 142, 263, 265,
 - 379
- tumor mass 65, 102, 103, 132,
 - 241, 316, 359
- tumor metastasis 27, 35, 63, 99,
 - 124, 126, 133, 390
- tumor microenvironment (TMC)
 - 3, 5, 56-63, 69, 71-73, 75-81,
 - 96, 97, 104, 105, 112,
 - 134-136, 144, 183, 185-187,
 - 191, 195-198, 233, 234,
 - 246-251, 254-256, 288, 289,
 - 316, 317, 359-372, 374-394,
 - 396-397
- tumor model 71, 73, 99, 301, 361,
 - 383, 390

- animal 22
- engineered 387
- human xenograft 141
- mammary mouse 73
- mouse lung 73
- murine neuroblastoma 295
- pancreatic mouse 69
- pancreatic murine 140
- scaffold-based engineered 388
- subcutaneous 144
- vascularized 386
- xenotransplantation breast 295
- tumor mutational burden 57
- tumor necrosis factor- α 30, 109, 265
- tumoroids 360, 363, 369, 394
- tumor progression 2, 3, 6, 7, 10, 28, 29, 38, 56, 58, 62, 123–130, 134, 135, 138, 147, 148, 248, 249, 251, 252, 326
- tumor-promoting effects 26, 32, 33, 361, 376
- tumor stromal cell 138, 288–290, 300
- tumor-stroma ratio (TSR) 8, 9
- tumor type 7, 33, 63, 66, 69, 74, 95, 289, 291, 292, 318, 319, 374, 375
- tumor vasculature 132, 135, 144, 265, 266, 317, 320, 321, 392, 395
- tumor suppressor 168, 169, 171, 173, 180
- tyrosine kinase inhibitor (TKI) 137, 143
- vascular endothelial growth factor (VEGF) 5, 7, 71–73, 102, 132, 143, 144, 147, 187, 190, 245, 250, 257, 258, 262, 301, 317, 318
- vascular endothelial growth factor receptor (VEGFR) 242, 244, 245, 256, 318
- vascular smooth muscle cell (VSMC) 101, 102, 187–189
- vasculature 94, 97, 98, 123, 125, 132, 139, 143, 147, 187, 202, 205, 386, 387, 389, 390
- VEGF *see* vascular endothelial growth factor
- VEGFR *see* vascular endothelial growth factor receptor
- VEGFR-1 245, 318
- VEGFR-2 244, 245, 318
- VEGFR-3 245, 320
- vimentin 101, 180, 194, 195, 328, 332, 378
- VSMC *see* vascular smooth muscle cell
- wound healing 2, 68, 102, 124, 171, 172, 182, 194, 195, 320, 332
- xenograft model 24, 107, 138, 139, 141, 202, 203, 260, 262, 265

“This book is a timely collection of scholarly articles dealing with the crucial and pivotal role of the tumor microenvironment (stroma) in carcinogenesis and tumor progression. It focuses on the biology and regulatory functions of resident or infiltrating stroma-associated cells (such as fibroblasts and macrophages) and on the molecular products of these cells. It discusses the often-neglected aspect dealing with the physical properties of the stroma and the therapeutic possibilities offered by the cancer–stroma crosstalk. I recommend the book to anyone interested in the interactions between tumors and their microenvironment.”

Prof. Emeritus Isaac P. Witz
Tel Aviv University, Israel

“Stromal components of tumor tissue are increasingly appreciated as critical to influencing disease progression and drug response. New single-cell and imaging technologies are unraveling the complex biology that underpins such processes, which promises to pave the way for new treatment strategies. This book assembles contributions from leading experts as a timely resource for investigators working across both fundamental and translational areas of cancer biology.”

Dr. Miles A. Miller
Harvard Medical School, USA

“This book provides a timely and comprehensive account of the emerging role of the tumor microenvironment during the course of malignant disease processes. Also, the prospects for using the tumor stroma as a biomarker or drug target for anticancer strategies is detailed by experts in the field. The book provides important insights for students and professionals alike and is a useful complementary reference work to tumor biology textbooks.”

Prof. Kristian Pietras
Lund University Cancer Centre, Sweden

“The limited success of cancer therapy, especially in advanced metastatic disease, warrants a more complete understanding of the nature of cancer cells and the factors that drive their proliferation and spread. Stromal cells in the tumor microenvironment significantly affect cancer cell characteristics and tumor fate by secreting a plethora of factors. Identifying the factors and cells that support the tumor microenvironment will open doors for new treatment modalities that target tumor-supporting stroma, thus offering novel strategies to fight cancer. This book presents a collection of studies describing the key cellular and molecular stromal components that support tumor progression.”

Dr. Yuval Shaked
Israel Institute of Technology, Israel



Jai Prakash, professor at the University of Twente in the Netherlands, is a pharmaceutical and bioentrepreneurial scientist working in the field of engineered therapeutics against cancer and fibrosis. He is educated as a pharmacologist and obtained his PhD (with honors) from the University of Groningen, the Netherlands. Earlier, he worked as vice president at BiOrion Technologies and assistant professor at Karolinska Institutet, Sweden, and then joined as tenure track professor at the University of Twente. He is also a founder and CSO of ScarTec Therapeutics and the president of BeNeLux and France local chapter for the Controlled Release Society (CRS). His research interests are in designing therapeutic technologies to disrupt the crosstalk between tumor cells and stromal cells and in developing advanced 3D *in vitro* models to mimic the tumor microenvironment.



JENNY STANFORD
PUBLISHING

